Search

Your search keyword '"Carteolol"' showing total 164 results

Search Constraints

Start Over You searched for: Descriptor "Carteolol" Remove constraint Descriptor: "Carteolol" Search Limiters Full Text Remove constraint Search Limiters: Full Text
164 results on '"Carteolol"'

Search Results

2. A comparative study between a transscleral sustained-release device and eyedrops on intraocular distribution of carteolol hydrochloride

3. Update on Treatment of Infantile Hemangiomas: What’s New in the Last Five Years?

4. Retinal Vessel Density Changes on Optical Coherence Tomography Angiography and Predictive Factors in Normal-Tension Glaucoma Treated with Topical Beta-Blocker.

8. Dose- and Time-Dependent Cytotoxicity of Carteolol in Corneal Endothelial Cells and the Underlying Mechanisms

9. Dose- and Time-Dependent Cytotoxicity of Carteolol in Corneal Endothelial Cells and the Underlying Mechanisms.

11. Enhancement in Corneal Permeability of Dissolved Carteolol by Its Combination with Magnesium Hydroxide Nanoparticles.

12. Latanoprost eye drops induce conjunctival lymphatic vessel development

13. Carteolol triggers senescence via activation of β-arrestin–ERK–NOX4–ROS pathway in human corneal endothelial cells in vitro.

14. Development and validation of UPLC/ESI-Q-TOF-MS for carteolol in aqueous humour: Stability, stress degradation and application in pharmacokinetics of nanoformulation

15. Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis

16. Bradycardia Shock Caused by the Combined Use of Carteolol Eye Drops and Verapamil in an Elderly Patient with Atrial Fibrillation and Chronic Kidney Disease

17. Life-threatening Vasospastic Angina Induced by Carteolol Eye Drops.

18. Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination

19. Cystoid Macular Edema Associated with Omidenepag Isopropyl in Phakic Eyes after Laser Iridotomy: A Case Report

20. Retinal Vessel Density Changes on Optical Coherence Tomography Angiography and Predictive Factors in Normal-Tension Glaucoma Treated with Topical Beta-Blocker

21. Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol

22. Carteolol hydrochloride reduces visible light-induced retinal damage in vivo and BSO/glutamate-induced oxidative stress in vitro

23. A comparative study between a transscleral sustained-release device and eyedrops on intraocular distribution of carteolol hydrochloride.

25. [Type IV hypersensitivity to timolol]

26. Hipersensibilidad tipo IV por timolol

27. Lipase Catalyzed Synthesis of Enantiopure Precursors and Derivatives for β-Blockers Practolol, Pindolol and Carteolol

28. Phosphorus dendrimers as powerful nanoplatforms for drug delivery, as fluorescent probes and for liposome interaction studies: A concise overview

29. Betaxolol, Brimonidin and Carteolol in the Therapy of Normal-Tension Glaucoma

30. Seasonal fluctuation in intraocular pressure and its associated factors in primary open-angle glaucoma

31. Lens-induced myopization and intraocular pressure in young guinea pigs

32. Changes in optic nerve head blood flow induced by the combined therapy of latanoprost and beta blockers.

33. Update on Treatment of Infantile Hemangiomas: What's New in the Last Five Years?

34. Enantioseparation of chiral β-blockers using polynorepinephrine-coated nanoparticles and chiral capillary electrophoresis

35. Effect of long-term topical latanoprost medication on conjunctival thickness in patients with glaucoma

36. A facile and efficient single-step approach for the fabrication of vancomycin functionalized polymer-based monolith as chiral stationary phase for nano-liquid chromatography

37. 'Tesofensine And Beta Blocker Combination Formulations' in Patent Application Approval Process (USPTO 20200129478)

38. Patent Issued for Tesofensine And Beta Blocker Combination Formulations (USPTO 10,537,551)

39. Patent Issued for Crystalline Form Of Benzylbenzene SGLT2 Inhibitor (USPTO 10,533,032)

40. Intraocular pressure with rebound tonometry and effects of topical intraocular pressure reducing medications in guinea pigs

41. Efficacy and safety of carteolol long-acting solution 2% compared with timolol gel-forming solution 0.5% in patients with primary open-angle glaucoma and ocular hypertension: A randomized, parallel-group, open-label phase IV study in Taiwan

42. Insidious-onset, non-wheezing carteolol-induced asthma in an atopic patient without asthma history

43. Bradycardia Shock Caused by the Combined Use of Carteolol Eye Drops and Verapamil in an Elderly Patient with Atrial Fibrillation and Chronic Kidney Disease.

44. Determination of Carteolol in Pure and Pharmaceutical Formulation by Spectrophotometric Method

45. 'Compositions For The Treatment Of Hypertension' in Patent Application Approval Process (USPTO 20190314383)

46. Simultaneous quantification of carteolol and dorzolamide in rabbit aqueous humor and ciliary body by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry

47. Enhancement in Corneal Permeability of Dissolved Carteolol by Its Combination with Magnesium Hydroxide Nanoparticles

48. [Type IV hypersensitivity to timolol].

49. Acute effect of topical carteolol on ocular pulsatile volume change

50. Cellular Cytotoxicity of Antiglaucoma Drugs in Cultured Corneal Endothelial Cells

Catalog

Books, media, physical & digital resources